Mzb treatment significantly reduced the percentage of ALDH1+ BCSCs from approximately 23% in control tumors to 4-5% (Figure 3E), suggesting that Mzb does not only impact the bulk-tumor population but also impacts BCSCs, and therefore regressed patient-derived tumors in vivo. The gene discussed is ALDH1A1; the disease is neoplasm.